BPR1M492─Novel and Fast Acting Opioid Analgesic
Technology Introduction:
Technology Introduction:This technology is a fast-acting dual-agonist that simultaneously activates μ-opioid receptor and nociceptin receptor, exhibiting high safety. It rapidly activates μ-opioid receptor to effectively relief pain. Additionally, it can reduce drug tolerance, enhance safety, and alleviate constipation by activating nociceptin receptor. The promotion of this technology will be facilitated through the postoperative pain market.
Industry Applicability:
‧ Innovation: Novel small molecule MOR/NOP dual agonist providing rapid pain relief.
‧ Safety Advantage: No hematological or biochemical toxicity, minimal gastrointestinal effects, and absence of tolerance development.
‧ Market Positioning: Best-in-class small molecule MOR/NOP dual agonist analgesic.
‧ IP Protection: Robust global patent protection for compound composition.
Industrial Applications:
-
National Health Research Institutes
National Health Research Institutes (NHRI) is a medical and health research organization in Taiwan, established as a public-funded foundation. Its main research areas include medicine, pharmaceuticals, public health, and other life sciences, as well as related technologies such as vaccine development.
